Several physical and pharmacological factors influence the efficiency of drug transfer across the placenta, including:
Placental Surface Area and Thickness: A larger surface area and thinner placental membrane increase the rate of diffusion.
pH of Maternal and Fetal Blood: Changes in blood pH alter the ionization of drugs, affecting their ability to cross the placenta. Because fetal pH is about 0.1 unit below maternal, weak bases such as local anesthetics and opioids are trapped in their ionized form on the fetal side, and fetal acidosis magnifies this ion trapping.
Placental Metabolism: The placenta expresses cytochrome P450 enzymes (notably CYP19 aromatase and CYP1A1) and phase II conjugating enzymes, but at far lower activity than the liver, so it metabolizes only a few drugs to a meaningful degree. The clearest example is 11-beta-hydroxysteroid dehydrogenase type 2, which inactivates cortisol and prednisolone before they reach the fetus while leaving betamethasone and dexamethasone largely untouched, the reason those two are the agents chosen to mature fetal lungs. Chloroprocaine is often credited with placental protection, but its rapid hydrolysis happens in maternal plasma, not the placenta.
Uteroplacental Blood Flow: Transfer of lipid-soluble drugs that cross the membrane easily (most anesthetic drugs) is flow-limited: the amount reaching the fetus per minute depends on how much maternal blood is delivered to the intervillous space, about 700 to 900 mL/min at term with no autoregulation. Poorly permeable drugs are instead membrane-limited. Reduced uteroplacental flow, as in pre-eclampsia, maternal hypotension, or aortocaval compression, limits both oxygen and drug delivery to the fetus, while maternal cardiac output and the interval between the dose and delivery set how much drug is presented to the placenta in the first place.
Fetal Circulation and First-Pass Uptake: What crosses the placenta is not what reaches the fetal brain. Drug returns to the fetus in the single umbilical vein. Most of that blood (roughly 70 to 80% in human Doppler studies, a smaller share in older animal work) passes through the fetal liver, where hepatic uptake and immature metabolism remove part of the dose, a fetal first-pass effect; the remainder bypasses the liver through the ductus venosus straight into the inferior vena cava. Umbilical venous blood is then diluted by deoxygenated blood returning from the fetal lower body and by the right heart before it reaches the brain. Together these steps mean the concentration arriving at the fetal brain after a single maternal induction dose is well below the umbilical venous level, one reason neonates are usually not obtunded after a standard dose of propofol given just before delivery.
| Factor | Effect on transfer |
|---|---|
| Molecular weight | Drugs under 500 Da cross more readily; most anesthetic drugs fall into this range and transfer efficiently |
| Lipid solubility | Lipophilic drugs diffuse more easily across the lipid-rich placental membranes |
| Degree of ionization | Non-ionized drug crosses more readily; the ionized fraction depends on the drug’s pKa and the pH on each side of the barrier. Fetal blood is more acidic, so weak bases (local anesthetics, opioids) are ion-trapped on the fetal side, more so in fetal acidosis |
| Protein binding | Highly protein-bound drugs cross poorly, since only the free fraction is available to diffuse |
| Placental surface area | A larger area increases the rate of diffusion, and surface area grows as pregnancy progresses |
| Membrane thickness | A thinner membrane speeds diffusion; infection or inflammation thickens the membrane and reduces efficiency |
| Placental metabolism | The placenta metabolizes some drugs, lowering the concentration that reaches the fetus |
| Uteroplacental blood flow | Adequate flow is required for efficient transfer; reduced flow, as in pre-eclampsia, limits drug availability to the fetus |
